Paladin launches Silenor in Canada
Silenor, which is not a controlled substance, will be made available in 3mg or 6mg oral tablets. Paladin interim president and chief executive officer Mark Beaudet said, "Canadians
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.
The AB-rated phenoxybenzamine hydrochloride capsule is the authorized generic of Dibenzyline. Prasco chief executive officer Chris Arington said, "Patients and customers alike benefit from WellSpring’s commitment to maintaining
Metronidazole 1.3% vaginal gel antibiotic development product is a topical antibiotic developed for the treatment of bacterial vaginosis. The agreement includes upfront and certain milestone payments in addition
Around 130 patients will be randomized with either OGX-427 or placebo in combination with ABRAXANE and gemcitabine therapy in the investigator-sponsored, placebo-controlled trial. The primary endpoint is overall